These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 15565908)

  • 1. Antimicrobial susceptibility patterns in Pseudomonas aeruginosa: data from a multicenter Intensive Care Unit Surveillance Study (ISS) in the United States.
    Friedland I; Gallagher G; King T; Woods GL
    J Chemother; 2004 Oct; 16(5):437-41. PubMed ID: 15565908
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo development of antimicrobial resistance in Pseudomonas aeruginosa strains isolated from the lower respiratory tract of Intensive Care Unit patients with nosocomial pneumonia and receiving antipseudomonal therapy.
    Riou M; Carbonnelle S; Avrain L; Mesaros N; Pirnay JP; Bilocq F; De Vos D; Simon A; Piérard D; Jacobs F; Dediste A; Tulkens PM; Van Bambeke F; Glupczynski Y
    Int J Antimicrob Agents; 2010 Dec; 36(6):513-22. PubMed ID: 20926262
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pseudomonas aeruginosa is not just in the intensive care unit any more: implications for empirical therapy.
    Eagye KJ; Banevicius MA; Nicolau DP
    Crit Care Med; 2012 Apr; 40(4):1329-32. PubMed ID: 22425824
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Decreased resistance of Pseudomonas aeruginosa with restriction of ciprofloxacin in a large teaching hospital's intensive care and intermediate care units.
    Lewis GJ; Fang X; Gooch M; Cook PP
    Infect Control Hosp Epidemiol; 2012 Apr; 33(4):368-73. PubMed ID: 22418632
    [TBL] [Abstract][Full Text] [Related]  

  • 5. National surveillance of antimicrobial resistance in Pseudomonas aeruginosa isolates obtained from intensive care unit patients from 1993 to 2002.
    Obritsch MD; Fish DN; MacLaren R; Jung R
    Antimicrob Agents Chemother; 2004 Dec; 48(12):4606-10. PubMed ID: 15561832
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of resistance, cross-resistance and antimicrobial combinations for Pseudomonas aeruginosa isolates from 1997 to 2009.
    Master RN; Clark RB; Karlowsky JA; Ramirez J; Bordon JM
    Int J Antimicrob Agents; 2011 Oct; 38(4):291-5. PubMed ID: 21737249
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibiotic susceptibility patterns of Pseudomonas aeruginosa to available antipseudomonal drugs in Ibadan, Nigeria.
    Ogbolu DO; Ogunledun A; Adebiyi OE; Daini OA; Alli AO
    Afr J Med Med Sci; 2008 Dec; 37(4):339-44. PubMed ID: 19301711
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro potency of amikacin and comparators against E. coli, K. pneumoniae and P. aeruginosa respiratory and blood isolates.
    Sutherland CA; Verastegui JE; Nicolau DP
    Ann Clin Microbiol Antimicrob; 2016 Jun; 15(1):39. PubMed ID: 27316973
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical, microbiologic, and epidemiologic characteristics of Pseudomonas aeruginosa infections in a University Hospital, Malatya, Turkey.
    Yetkin G; Otlu B; Cicek A; Kuzucu C; Durmaz R
    Am J Infect Control; 2006 May; 34(4):188-92. PubMed ID: 16679175
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Susceptibility of Pseudomonas aeruginosa clinical isolates in Japan to doripenem and other antipseudomonal agents.
    Fujimura T; Anan N; Sugimori G; Watanabe T; Jinushi Y; Yoshida I; Yamano Y
    Int J Antimicrob Agents; 2009 Dec; 34(6):523-8. PubMed ID: 19748767
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of a program to reduce hospital ciprofloxacin use on nosocomial Pseudomonas aeruginosa susceptibility to quinolones and other antimicrobial agents.
    Cook PP; Das TD; Gooch M; Catrou PG
    Infect Control Hosp Epidemiol; 2008 Aug; 29(8):716-22. PubMed ID: 18590455
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Surveillance for antimicrobial susceptibility among clinical isolates of Pseudomonas aeruginosa and Acinetobacter baumannii from hospitalized patients in the United States, 1998 to 2001.
    Karlowsky JA; Draghi DC; Jones ME; Thornsberry C; Friedland IR; Sahm DF
    Antimicrob Agents Chemother; 2003 May; 47(5):1681-8. PubMed ID: 12709340
    [TBL] [Abstract][Full Text] [Related]  

  • 13. National survey of susceptibility to antimicrobials amongst clinical isolates of Pseudomonas aeruginosa.
    Chen HY; Yuan M; Ibrahim-Elmagboul IB; Livermore DM
    J Antimicrob Chemother; 1995 Apr; 35(4):521-34. PubMed ID: 7628986
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multicentre surveillance of Pseudomonas aeruginosa susceptibility patterns in nosocomial infections.
    Van Eldere J
    J Antimicrob Chemother; 2003 Feb; 51(2):347-52. PubMed ID: 12562701
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Resistance Rates of Intra-Abdominal Isolates from Intensive Care Units and Non-Intensive Care Units in the United States: The Study for Monitoring Antimicrobial Resistance Trends 2010-2012.
    Hackel MA; Badal RE; Bouchillon SK; Biedenbach DJ; Hoban DJ
    Surg Infect (Larchmt); 2015 Jun; 16(3):298-304. PubMed ID: 25894976
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phenotypic antimicrobial resistance patterns in Pseudomonas aeruginosa and Acinetobacter: results of a Multicenter Intensive Care Unit Surveillance Study, 1995-2000.
    Friedland I; Stinson L; Ikaiddi M; Harm S; Woods GL
    Diagn Microbiol Infect Dis; 2003 Apr; 45(4):245-50. PubMed ID: 12729994
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pseudomonas aeruginosa Antimicrobial Susceptibility Results from Four Years (2012 to 2015) of the International Network for Optimal Resistance Monitoring Program in the United States.
    Sader HS; Huband MD; Castanheira M; Flamm RK
    Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28069652
    [No Abstract]   [Full Text] [Related]  

  • 18. Stable antimicrobial susceptibility rates for clinical isolates of Pseudomonas aeruginosa from the 2001-2003 tracking resistance in the United States today surveillance studies.
    Karlowsky JA; Jones ME; Thornsberry C; Evangelista AT; Yee YC; Sahm DF
    Clin Infect Dis; 2005 Feb; 40 Suppl 2():S89-98. PubMed ID: 15712102
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Combination Antibiogram Evaluation for
    Puzniak L; DePestel DD; Srinivasan A; Ye G; Murray J; Merchant S; DeRyke CA; Gupta V
    Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30917987
    [No Abstract]   [Full Text] [Related]  

  • 20. Changes in the rates of antimicrobial resistance among clinical isolates of Pseudomonas aeruginosa between 2002 and 2004 in a tertiary-care teaching hospital in Turkey.
    Işeri L; Bayraktar MR
    New Microbiol; 2008 Jul; 31(3):351-5. PubMed ID: 18843889
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.